New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism

@article{Tran2019NewGF,
  title={New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism},
  author={Huyen A Tran and Harry Gibbs and Eileen Merriman and Jennifer Curnow and Laura Young and Ashwini Bennett and Tan Chee Wee and Sanjeev D Chunilal and Chris M Ward and Ross I. Baker and Harshal H Nandurkar},
  journal={Medical Journal of Australia},
  year={2019},
  volume={210}
}
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cardiovascular disease and, globally, more than an estimated 10 million people have it yearly. It is a chronic and recurrent disease. The symptoms of VTE are non‐specific and the diagnosis should actively be sought once considered. The mainstay of VTE treatment is anticoagulation, with few patients requiring additional intervention. 
Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents.
TLDR
How recent advances in the understanding and management of venous thromboembolism are changing practice are discussed, ongoing unmet needs in VTE management are highlighted, and how novel therapeutic targets with little or no influence on hemostasis may help address these un met needs are outlined. Expand
Venous thromboembolism: current management
TLDR
Monotherapy with rivaroxaban or apixaban is the preferred option for most adults with acute venous thromboembolism and both drugs have low rates of major bleeding. Expand
Anticoagulation in Deep Venous Thrombosis: Current Trends in the Era of Non-Vitamin K Antagonists Oral Anticoagulants.
TLDR
There are issues about their efficacy and safety profile in specific populations with high thromboembolic and bleeding risks such as renal failure patients, active-cancer patients, and pregnant women, in which VKAs and heparins were the standard care of treatment. Expand
Individualised Risk Assessments for Recurrent Venous Thromboembolism: New Frontiers in the Era of Direct Oral Anticoagulants
TLDR
There is a need for an individualised, targeted approach for assessing the risk of VTE recurrence, especially in those patients in whom the balance between benefit and risk of long-term anticoagulation is not clear. Expand
The current place of direct oral anticoagulants in the prevention/treatment of venous thromboembolism
TLDR
For acute VTE treatment and secondary prevention, DOACs are recommended as the first-line therapy in the general population and should be made mainly according to patient characteristics and pharmacokinetic properties of the drug. Expand
Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities
TLDR
The current strategies used to predict the development of recurrent VTE are reviewed, with emphasis on the application of several promising novel biomarkers in this field. Expand
ROTEM Testing for Direct Oral Anticoagulants.
TLDR
Rotational thromboelastometry (ROTEM) is a viscoelastic hemostatic assay (VHA) which has been used in emergencies, and surgical procedures, but experience with this assay in DOACs-treated patients is still limited, and this article reviews the use of ROTEM in the setting ofDOACs therapy. Expand
Managing Thromboembolic Risk in Patients with Hereditary and Acquired Thrombophilias.
TLDR
This review focuses on cases in which patients have been identified as having thrombophilic defects rather than the indications for undertaking testing in the first place or the extent of investigation, and particular attention to transient acquired risk factors for VTE remains paramount. Expand
Thrombophilia evaluation in pulmonary embolism.
TLDR
Thrombophilia testing in its current form does not significantly impact clinical management or improve outcomes for most VTE patients, so it should be employed judiciously and only in patients for whom it is likely to alter clinical management. Expand
Venous thromboembolism prophylaxis practice and its association with outcomes in Australia and New Zealand burns patients
TLDR
Variation in the use of VTE prophylaxis was observed between the units, and prophyllaxis use was associated with a decrease in the odds of mortality. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 55 REFERENCES
Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism
Essentials The long‐term risk of recurrence and death after distal deep vein thrombosis (DVT) is uncertain. We included subjects with first proximal or isolated distal DVT (IDDVT) and no pulmonaryExpand
The incidence of venous thromboembolism: a prospective, community‐based study in Perth, Western Australia
Objective: To determine the incidence of venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), in a well defined urban community broadly representative ofExpand
D‐Dimer for venous thromboembolism diagnosis: 20 years later
TLDR
The present narrative review updates the data available on the use of the various commercially available DD assays in the diagnostic approach of clinically suspected VTE in distinct patient populations or situations, including outpatients and inpatients, patients with cancer, older age, pregnancy, a suspected recurrent event, limited thrombus burden, and patients already on anticoagulant treatment. Expand
Isolated distal deep vein thrombosis: what we know and what we are doing
TLDR
There is insufficient data to support the diagnosis and treatment of all IDDVTs, and the necessary criteria to identify subjects at higher risk of complication are lacking, so it seems likely that different approaches may be better for unprovoked or secondary events and for deep or muscle veins. Expand
Acute venous thromboembolism in patients with recent major bleeding. The influence of the site of bleeding and the time elapsed on outcome
TLDR
The incidence of new bleeding or death depends on the site of prior bleeding and the time elapsed until VTE, and this information may help to identify the best therapeutic approach for these high‐risk patients. Expand
Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism
TLDR
A meta-analysis of studies involving patients with venous thromboembolism who received at least 3 months of oral anticoagulant therapy with a target international normalized ratio (INR) of 2.0 to 3.0 obtained reliable estimates of the clinical impact of anticogulant-related bleeding. Expand
Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta‐analysis
TLDR
Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study is presented. Expand
The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S.
TLDR
Patients with AT deficiency are potential candidates for long-term oral anticoagulation, and the carriers of PC or PS deficiency had a marginal increase in risk of recurrence. Expand
Thrombosis: a major contributor to global disease burden.
TLDR
VTE associated with hospitalization was the leading cause of disability-adjusted-life-years lost in low- and middle-income countries, and second in high- income countries, responsible for more DALYs lost than nosocomial pneumonia, catheter-related blood stream infections, and adverse drug events. Expand
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
TLDR
The primary effectiveness and safety outcomes were major bleeding, recurrent venous thromboembolism, and all-cause mortality, and rivaroxaban-treated patients had a lower risk profile at baseline than those treated with standard anticoagulation. Expand
...
1
2
3
4
5
...